Atovaquone and proguanil versus pyrimethamine/sulfadoxine for the treatment of acute falciparum malaria in Zambia (Q39279868)

10 September 2017

Atovaquone and proguanil versus pyrimethamine/sulfadoxine for the treatment of acute falciparum malaria in Zambia (English)

1 reference

10 September 2017

0 references

0 references

Plasmodium falciparum

0 references

0 references

1 reference

Mulenga M

1

1 reference

10 September 2017

Sukwa TY

series ordinal

2

1 reference

10 September 2017

Canfield CJ

series ordinal

3

1 reference

10 September 2017

Hutchinson DB

series ordinal

4

1 reference

10 September 2017

1 May 1999

1 reference

10 September 2017

Clinical Therapeutics

1 reference

10 September 2017

21

1 reference

10 September 2017

841-852

1 reference

10 September 2017

5

1 reference

Stevens-Johnson syndrome after mass prophylaxis with sulfadoxine for cholera in Mozambique

10 September 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2899%2980006-X

7 January 2021

Severe cutaneous reactions among American travelers using pyrimethamine-sulfadoxine (Fansidar) for malaria prophylaxis.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2899%2980006-X

7 January 2021

Fatal hepatic necrosis due to pyrimethamine-sulfadoxine (Fansidar).

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2899%2980006-X

7 January 2021

Neuropsychiatric side effects after the use of mefloquine

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2899%2980006-X

7 January 2021

Cardiac effects of antimalarial treatment with halofantrine.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2899%2980006-X

7 January 2021

Cardiac complications of halofantrine: a prospective study of 20 patients

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2899%2980006-X

7 January 2021

Site of action of the antimalarial hydroxynaphthoquinone, 2-[trans-4-(4'-chlorophenyl) cyclohexyl]-3- hydroxy-1,4-naphthoquinone (566C80)

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2899%2980006-X

7 January 2021

Interactions of atovaquone with other antimalarial drugs against Plasmodium falciparum in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2899%2980006-X

7 January 2021

Clinical studies of atovaquone, alone or in combination with other antimalarial drugs, for treatment of acute uncomplicated malaria in Thailand

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2899%2980006-X

7 January 2021

Atovaquone and proguanil for Plasmodium falciparum malaria.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2899%2980006-X

7 January 2021

Atovaquone and proguanil for the treatment of malaria in Brazil.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2899%2980006-X

7 January 2021

Examination of some factors responsible for a food-induced increase in absorption of atovaquone

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2899%2980006-X

7 January 2021

Malarone (atovaquone and proguanil hydrochloride): a review of its clinical development for treatment of malaria. Malarone Clinical Trials Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2899%2980006-X

7 January 2021

Sensitivity of Plasmodium falciparum in vivo to chloroquine and pyrimethamine-sulfadoxine in Rwandan patients in a refugee camp in Zaire

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2899%2980006-X

7 January 2021

Plasmodium falciparum: susceptibility in vitro and in vivo to chloroquine and sulfadoxine-pyrimethamine in Ghanaian schoolchildren.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2899%2980006-X

7 January 2021

In vitro susceptibility of Plasmodium falciparum to chloroquine, amodiaquine, quinine, mefloquine, and sulfadoxine/pyrimethamine in Equatorial Guinea

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2899%2980006-X

7 January 2021

Drug resistance among malaria and other parasites

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2899%2980006-X

7 January 2021

Efficacy and safety of atovaquone/proguanil as suppressive prophylaxis for Plasmodium falciparum malaria

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2899%2980006-X

7 January 2021

Randomised placebo-controlled study of atovaquone plus proguanil for malaria prophylaxis in children

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2899%2980006-X

7 January 2021

10.1016/S0149-2918(99)80006-X

Identifiers

DOI

1 reference

10 September 2017

1 reference